These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32158550)

  • 1. Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting.
    Weng W; Tian Y; Kong SX; Ganguly R; Hersloev M; Brett J; Hobbs T
    Clin Diabetes Endocrinol; 2020; 6():5. PubMed ID: 32158550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of atherosclerotic cardiovascular disease risk and healthcare costs in newly diagnosed type 2 diabetes in a real-world setting.
    Weng W; Liang Y; Brett J; Hobbs T; Baeres FMM
    J Diabetes Complications; 2020 May; 34(5):107500. PubMed ID: 32173216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database.
    Zhao Z; Zhu Y; Fang Y; Ye W; McCollam P
    J Med Econ; 2015; 18(9):655-65. PubMed ID: 25891183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real-world population with type 2 diabetes.
    Weng W; Kong SX; Ganguly R; Hersloev M; Brett J; Hobbs T; Baeres FMM
    Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00106. PubMed ID: 32318629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
    Raju A; Pimple P; Stafkey-Mailey D; Farrelly E; Shetty S
    Diabetes Ther; 2022 Jan; 13(1):25-42. PubMed ID: 34727356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs.
    Yi Y; Li Y; Hou A; Ge Y; Xu Y; Xiong G; Yang X; Acevedo SA; Shi L; Xu H
    Diabetes Ther; 2018 Jun; 9(3):1073-1082. PubMed ID: 29623592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
    Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
    Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.
    Power TP; Ke X; Zhao Z; Bonine NG; Cziraky MJ; Grabner M; Barron JJ; Quimbo R; Vangerow B; Toth PP
    Vasc Health Risk Manag; 2018; 14():23-36. PubMed ID: 29440909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease.
    Jafar Z; Valero-Elizondo J; Saeed GJ; Acquah I; Yahya T; Mahajan S; Mszar R; Khan SU; Caínzos-Achirica M; Nasir K
    Am J Prev Cardiol; 2020 Sep; 3():100084. PubMed ID: 34327464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany - results of a claims database study.
    Sidelnikov E; Dornstauder E; Jacob C; Maas C; Pinto L; Leidl R; Ahrens I
    J Med Econ; 2022; 25(1):1199-1206. PubMed ID: 36330899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
    Weng W; Tian Y; Kong SX; Ganguly R; Hersloev M; Brett J; Hobbs T
    Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00076. PubMed ID: 31294089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.
    Chen S; Fu AC; Jain R; Tan H
    Am Health Drug Benefits; 2015 Apr; 8(2):71-80. PubMed ID: 26005514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.